{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:21:54Z","timestamp":1783506114760,"version":"3.55.0"},"reference-count":26,"publisher":"MDPI AG","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAPMA"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:p>\n                    This study was conducted to investigate the efficacy of oral terbinafine with and without aggressive debridement for the treatment of toenail onychomycosis. Onychomycosis patients aged 18 to 75 years received 12 weeks of terbinafine, 250 mg\/day, alone (n = 255) or with aggressive debridement (n = 249). Both groups showed marked improvement from baseline at all time points. At week 48, complete, mycologic, and clinical cure rates were higher in the terbinafine plus debridement group compared with the terbinafine alone group, although significance was reached only for clinical cure (59.8%\n                    <jats:italic>versus<\/jats:italic>\n                    51.4%;\n                    <jats:italic>P<\/jats:italic>\n                    = .023). Although approximately 39% of the patients received at least one antidiabetic, antihypertensive, or cholesterol-lowering agent concomitantly, including statins, the incidence of treatment-emergent adverse events was low and the adverse events were generally mild to moderate in severity. No clinically significant changes in liver transaminase levels were observed 6 weeks after treatment or after 12 weeks in those tested. These results support the well-established safety and efficacy of terbinafine for treatment of onychomycosis. (J Am Podiatr Med Assoc 96(6): 465\u2013473, 2006)\n                  <\/jats:p>","DOI":"10.7547\/0960465","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T10:22:47Z","timestamp":1396347767000},"page":"465-473","source":"Crossref","is-referenced-by-count":33,"title":["Treatment of Toenail Onychomycosis with Oral Terbinafine Plus Aggressive Debridement"],"prefix":"10.3390","volume":"96","author":[{"given":"Maureen B.","family":"Jennings","sequence":"first","affiliation":[{"name":"New York College of Podiatric Medicine, New York, NY. Dr. Jennings is now with the Jennings Institute for Clinical Research, Fort Lee, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pollak","sequence":"additional","affiliation":[{"name":"San Antonio Podiatry Associates, San Antonio, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Harkless","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Kianifard","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corp, East Hanover, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Tavakkol","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corp, East Hanover, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"R1","series-title":"Qual Life Res","first-page":"341","volume":"2","year":"1993","unstructured":"Lubeck DP, Patrick DL, McNulty P, et al: Quality of life of persons with onychomycosis. .Qual Life Res2::341. ,1993. .8136799"},{"key":"R2","series-title":"Br Med J","first-page":"1591","volume":"318","year":"1999","unstructured":"Dupuy A, Benchikhi H, Roujeau JC, et al: Risk factors for erysipelas of the leg (cellulitis): case-control study. .Br Med J318::1591. ,1999. ."},{"key":"R3","series-title":"Dermatology","first-page":"301","volume":"209","year":"2004","unstructured":"Roujeau JC, Sigurgeirsson B, Korting HC, et al: Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. .Dermatology209::301. ,2004. .15539893"},{"key":"R4","series-title":"Drug Safety","first-page":"33","volume":"22","year":"2000","unstructured":"Gupta AK, Shear NH: A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. .Drug Safety22::33. ,2000. .10647975"},{"key":"R5","series-title":"JAPMA","first-page":"502","volume":"90","year":"2000","unstructured":"Gupta AK, Malkin KF: Ciclopirox nail lacquer and podiatric practice. .JAPMA90::502. ,2000. ."},{"key":"R6","series-title":"J Diabetes Compl","first-page":"98","volume":"17","year":"2003","unstructured":"Robbins JM: Treatment of onychomycosis in the diabetic patient population. .J Diabetes Compl17::98. ,2003. ."},{"key":"R7","series-title":"Br J Dermatol","first-page":"1177","volume":"142","year":"2000","unstructured":"Baran R, Feuilhade M, Combernale P, et al: A randomized trial of amoroline 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. .Br J Dermatol142::1177. ,2000. .10848743"},{"key":"R8","series-title":"J Am Acad Dermatol","first-page":"912","volume":"9","year":"1983","unstructured":"Drachmand ZM: A method for the determination of drug effectiveness in onychomycosis. .J Am Acad Dermatol9::912. ,1983. .6315789"},{"key":"R9","year":"2004","unstructured":"Jennings M, Harkless LB, Pollak RA: Quantitation of visibly infected nail area in onychomycosis utilizing the mycotic nail involvement assessment [abstract]. Presented at the Annual Scientific Meeting of the American Podiatric Medical Association, August 24. ,2004. , Boston."},{"key":"R10","year":"2004","unstructured":"Lamisil [prescribing information], Novartis Pharmaceutical Corp, East Hanover, NJ, May. 2004. ."},{"key":"R11","year":"2000","unstructured":"Stokes ME, Davis CS, Koch GG: Categorical Data Analysis Using the SAS System, 2nd Ed, SAS Institute Inc, Cary, NC. ,2000. ."},{"key":"R12","series-title":"Br J Dermatol","first-page":"18","volume":"134","year":"1996","unstructured":"Brautigam M, Nolting S, Schopf RE, et al: German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. .Br J Dermatol134: (suppl 46):18. ,1996. .8763463"},{"key":"R13","series-title":"Br J Dermatol","first-page":"16","volume":"134","year":"1996","unstructured":"De Backer M, De Kayser P, De Vroey C, et al: A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg\/day vs itraconazole 200 mg\/day: a double-blind comparative trial. .Br J Dermatol134: (suppl 46):16. ,1996. .8763462"},{"key":"R14","series-title":"Arch Dermatol","first-page":"353","volume":"138","year":"2002","unstructured":"Sigurgeirsson B, O\u0301lafsson JH, Steinsson J, et al: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. .Arch Dermatol138::353. ,2002. .11902986"},{"key":"R15","series-title":"Br Med J","first-page":"919","volume":"311","year":"1995","unstructured":"Brautigam M, Nolting S, Schopf RE, et al: Randomized double-blind comparison of terbinafine and itraconazole in the treatment of toenail tinea infection. .Br Med J311::919. ,1995. ."},{"key":"R16","series-title":"JAPMA","first-page":"127","volume":"91","year":"2001","unstructured":"Pollak R, Billstein SA: Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations. .JAPMA91::127. ,2001. ."},{"key":"R17","series-title":"Br Med J","first-page":"1151","volume":"304","year":"1992","unstructured":"Goodfield MJ, Andrew L, Evans EG: Short term treatment of dermatophyte onychomycosis with terbinafine. .Br Med J304::1151. ,1992. ."},{"key":"R18","series-title":"J Am Acad Dermatol","first-page":"S57","volume":"38","year":"1998","unstructured":"DeBacker M, DeVroey C, Lesaffre E, et al: Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind, comparative trial of terbinafine 250 mg\/day versus itraconazole 200 mg\/day. .J Am Acad Dermatol38::S57. ,1998. .9594939"},{"key":"R19","series-title":"J Drugs Dermatol","first-page":"302","volume":"4","year":"2005","unstructured":"Gupta AK, Ryder JE, Tavakkol A: The use of terbinafine in the treatment of onychomycosis in adults and special patient populations: a review of the evidence. .J Drugs Dermatol4::302. ,2005. .15898285"},{"key":"R20","series-title":"JAPMA","first-page":"421","volume":"95","year":"2005","unstructured":"Arnold B, Kianifard F, Tavakkol A: A comparison of KOH and culture results from two mycology laboratories for the diagnosis of onychomycosis during a randomized, multicenter clinical trial: a subset study [letter]. .JAPMA95::421. ,2005. ."},{"key":"R21","series-title":"J Am Acad Dermatol","first-page":"765","volume":"37","year":"1997","unstructured":"Singer MI, Shapiro LE, Shear NH: Cytochrome P-450 3A: interactions with dermatologic therapies. .J Am Acad Dermatol37::765. ,1997. .9366824"},{"key":"R22","series-title":"Drug Metab Dispos","first-page":"1029","volume":"27","year":"1999","unstructured":"Vickers AEM, Sinclair JR, Zollinger M, et al: Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. .Drug Metab Dispos27::1029. ,1999. .10460803"},{"key":"R23","series-title":"Clin Ther Risk Manage","first-page":"299","volume":"1","year":"2005","unstructured":"Elewski B, Tavakkol A: Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. .Clin Ther Risk Manage1::299. ,2005. ."},{"key":"R24","series-title":"J Am Acad Dermatol","first-page":"237","volume":"41","year":"1999","unstructured":"Gupta AK, Katz I, Shear NH: Drug interactions with itraconazole, fluconazole, and terbinafine and their management. .J Am Acad Dermatol41::237. ,1999. .10426895"},{"key":"R25","series-title":"Arch Dermatol","first-page":"1213","volume":"133","year":"1997","unstructured":"Hall M, Monka C, Krupp P, et al: Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. .Arch Dermatol133::1213. ,1997. .9382559"},{"key":"R26","series-title":"Am J Geriatr Pharmacol","first-page":"1","volume":"4","year":"2006","unstructured":"Tavakkol A, Fellman S, Kianifard F: Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in the open-label, randomized Improving Results in Onychomycosis Concomitant Lamisil\u00ae and Debridement (IRON-CLAD\u00ae) trial. .Am J Geriatr Pharmacol4::1. ,2006. ."}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/japmaonline.org\/view\/journals\/apms\/96\/6\/0960465.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/96\/6\/465\/1412550\/0960465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/96\/6\/0960465.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/96\/6\/0960465.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:10:59Z","timestamp":1783505459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/96\/6\/465"}},"subtitle":["IRON-CLAD, a Large, Randomized, Open-Label, Multicenter Trial"],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":26,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.7547\/0960465","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}